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The growth of solid tumours and their metastases is dependent on the develop-
ment of new blood vessels (angiogenesis). Therefore angiogenesis inhibitors are
potential antitumour drugs.
In our previous studies it was found that the angiogenesis inhibitor TNP-470
given to transplantable melanoma-bearing hamsters can decrease the rate of
the tumour growth, although the survival time of the animals treated was not
significantly affected. It was found finally that TNP-470 given in the vicinity of
the growing tumour can cause complete remission of the melanoma in ham-
sters treated in this way. To check what side-effects could be evoked by such
treatment, an examination of the morphology of the blood vessels of the lungs,
kidneys and livers of the treated animals was carried out. It was found that the
angiogenesis inhibitor applied did not cause any changes which could be ob-
served by light and electron microscopes in the structure of the examined blood
vessels of the treated animals.
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INTRODUCTION
It is well recognised that angiogenesis has es-
sential significance for the growth of solid tumours
[4, 5, 10]. Therefore many angiogenesis inhibitors
have been examined as potential antitumour drugs. One
of the most promising as a future antitumour drug ap-
pears to be the synthetic fumagilin analogue TNP-470
[3, 6–8]. In our previous studies on that compound
we achieved some effect in the suppression of the
growth of the transplantable melanoma in hamsters.
The growth rate of this tumour was significantly
decreased but the survival time of the tumour-bear-
ing animals was prolonged only slightly [12, 13]. In
our last published studies we found that TNP-470
given in the vicinity of a growing tumour can cause
complete remission of Bomirski Ab amelanotic mel-
anoma and prevent the development of its metastas-
es [14]. The success of such treatment for a fast-
growing tumour that is able to kill a hamster in sev-
eral weeks indicates that TNP-470 can be one of the
most effective antitumour drugs. However, there is
the problem of side-effects, which in the case of ef-
fective antitumour drugs is usually very serious. In
our successful studies TNP-470 was given in the vi-
cinity of a growing tumour, so the dose of this com-
pound applied could be comparatively low. Even so,
the systemic action of TNP-470 was inescapable. We
therefore decided to test the effect of the strong
antiangionesis inhibitor TNP-470 on the blood ves-
sels of the lungs, kidneys and livers of the treated
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hamsters. Since the action of TNP-470 was found to
be directed at the endothelial cells [3, 9], our atten-
tion was mainly concentrated on the endothelium
of the vessels examined.
MATERIAL AND METHODS
TNP-470 was the kind gift of Takeda Chemical In-
dustries (Osaka, Japan). The chemical structure of the
compound has been presented by Ingbar et al. [8].
Forty random-bred Syrian (golden) male hamsters
were used in the study. They were obtained from
the animal colony of the Silesian Medical University
(Katowice, Poland) and maintained in our colony on
a standard diet and water ad libitum. The care and
treatment of the animals were in accordance with
the “European Convention for the Protection of Ver-
tebrate Animals Used for Experimental and Other
Scientific Purposes”. The study was approved by the
Local Committee for Animal Experiments, Gdańsk,
Poland.
Bomirski melanoma variant Ab was maintained
by serial passage in the hamsters using the suspen-
sion method of tumour transplantation. The natural
history and characteristics of this melanoma are de-
scribed by Bomirski et al. [2]. The tumour cells were
always implanted on the right flank of the animals
by subcutaneous (s.c.) injection.
TNP-470 in a suspension vehicle composed of 1%
ethanol and 5% Arabic gum in a saline was given
s.c. at a dose of 30 mg/kg (about 3.9 mg/animal in
500 mL of vehicle) in the vicinity of the palpable tu-
mour every day for 21 days. The control tumour-
bearing animals received injections of vehicle. All
animals were sacrificed on the 28th day from the
beginning of the experiment.
Sample preparation for histological examination
Small blocks of the organs under examination
were put into a 4% formaldehyde solution in PBS.
After being washed in water and dehydrated in eth-
anol, the tissue was embedded in paraffin. Sections
of the examined tissues were stained with eosine
and haematoxylin. Photographs were taken with
a Nikon E800 microscope.
Sample preparation for the electron microscope
The hamsters were anaesthetised by an intraperi-
toneal injection of pentobarbital sodium (50 mg/kg).
The animals were perfused transcardially with 50 ml
of 0.9% saline containing 500 heparin units, and then
perfused with a fixative composed of 4% paraform-
aldehyde and 1% glutaraldehyde in a 0.05 M phos-
phate buffer (pH 7.4) containing 0.03% CaCl2. Blocks
of tissues were rapidly removed and post-fixed in
the same fixative overnight at 4oC. Next each spec-
imen was briefly rinsed in a 0.1 M phosphate buff-
er containing CaCl2 at room temperature, and then
post-fixed for 1 hour in 1% osmium tetroxide. After
being dehydrated in increasing concentrations of al-
cohol and  propylene oxide, the specimens were em-
bedded in Epon 812. The ultrathin sections were
stained with uranyl acetate and lead citrate and ex-
amined with a JEM 1200EX II electron microscope.
RESULTS
Lungs
The structure of blood vessels of various sizes
from hamsters, both healthy and tumour-bearing
ones, which had been treated with TNP-470 did not
differ when examined by light microscope from
those of untreated animals (Fig. 1). Endothelial cells
did not show any symptoms of histological lesions.
Also the ultrastructure of the endothelial cells of
the lung vessels from the treated hamsters was
normal (Fig. 2).
Kidneys
The capillaries of the renal glomerules from ani-
mals treated with TNP-470 did not differ from those
of the untreated animals, both under a light micro-
scope (Fig. 3, 4) and under an electron microscope
(Fig. 5, 6). The larger blood vessels also had a nor-
mal structure, both for the treated and the untreat-
ed animals.
Livers
The structure of the blood vessels of various sizes,
lobular and interlobular (Fig. 7), from the livers of the
treated animals was similar to those of the untreated
animals and no symptoms of histological lesions were
noticeable. The ultrastructure of the endothelium of
the examined vessels also seemed to be normal (Fig. 8).
The presence of the tumour in animals had no
effect on the structure of the vessels of the exam-
ined organs.
DISCUSSION
The results of our studies indicate that the an-
giogenesis inhibitor TNP-470, which is able to cause
a complete remission of a fast-growing tumour, led
neither to changes in the structure, nor probably the
function, of the blood vessels of such important or-
gans as the lungs, kidneys and livers. The period of
treatment with TNP-470 was 21 days, which is short
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in comparison to the duration of the administration
of the antitumour drugs applied in oncology. This
was, in any case, sufficient time for recovery for ham-
sters bearing transplantable melanoma. The good
state of the structure of the endothelium and other
parts of the blood vessel walls examined by light and
electron microscopes did not preclude changes in
the function of these vessels. However, if such chang-
es had occurred, they were reversible, since the ani-
mals which survived treatment with TNP-470 were
examined 5 months after the last injection of that
drug and were found to be healthy [14]. The angio-
genesis inhibitor TNP-470, therefore, appeared in our
studies to be both effective as an antitumour drug
and harmless to the animals treated. These results
were achieved with an animal model and, at present,
it is difficult to make any claims as to whether such
a good effect would be possible in humans. TNP-470
is already undergoing pre-clinical investigations [1, 6]
but reports about the side-effects of such treatment
Figure 1. Lung of a melanoma-bearing hamster treated with
TNP-470. Cross-section of a branch of the pulmonary artery.
Both the endothelium and the thin media are normal in structure;
bv — blood vessel, p — lung parenchyma. Staining with eosine
and haematoxylin. Bar: 50 mm.
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Figure 3. Renal corpuscle of the kidney of a melanoma-bearing
hamster treated with TNP-470. Glomerular vessels have normal
structure; g — renal glomerule, p — renal parenchyma. Staining
with eosine and haematoxylin. Bar: 50 mm.
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Figure 4. Blood vessel in the renal cortex of a melanoma-bear-
ing hamster treated with TNP-470. Both endothelium and me-
dia demonstrate normal structure; bv — blood vessel, p — re-
nal parenchyma. Staining with eosine and haematoxylin. Bar:
50 mm.
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Figure 2. Lung of a melanoma-bearing hamster treated with
TNP-470. Cross sections of blood capillaries (b cap) in the lung
parenchyma. Blood capillaries demonstrate normal ultrastructure
of the endothelium. Bar: 1 mm.
2 1 mm
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in humans are rather scanty and limited to such ob-
servations as the occurrence of nausea and fatigue,
and the presence of some neurological symptoms
which disappeared after therapy was discontinued
[6]. Examinations of the effect of TNP-470 on en-
dothelial cells were mainly carried out on endothe-
lial cells cultured in vitro [3]. In our studies TNP-470
was given in the vicinity of a growing tumour, so
that the dose applied of that compound could be
quite low. The systemic action of TNP-470 was un-
Figure 6. Renal corpuscle of the kidney of a melanoma-bearing
hamster treated with TNP-470. Endothelium of the glomerular
capillary (g cap) demonstrates normal ultrastructure;
p — podocyte. Bar: 2 mm.
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Figure 7. Liver of a melanoma-bearing hamster treated with
TNP-470.  Longitudinal section of interlobular blood vessel (bv)
and interlobular bile duct (bd) surrounded by liver parenchyma
(p). The blood vessel demonstrates normal structure. Staining
with eosine and haematoxylin. Bar: 50 mm.
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Figure 5. Renal corpuscle of the kidney of a healthy hamster;
g cap — glomerular capillary, p — podocyte. Bar: 2 mm.
5
Figure 8. Liver of a melanoma-bearing hamster treated with
TNP-470. Cross-section of the liver sinusoid (ls) surrounded by
liver parenchyma (p). The endothelium of the sinusoid demon-
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avoidable. We decided, therefore, to test the influ-
ence that a strong antiangiogenesis inhibitor could
exert on the blood vessels of the lungs, kidneys and
liver of the hamsters treated with TNP-470. The prob-
lem of the possible side-effects of the treatment with
TNP-470 is very important since the only partly ef-
fective action of that drug in pre-clinical trails in-
duced some research groups to apply a combined
treatment with other antitumour drugs, which them-
selves sometimes cause severe side-effects [6, 11].
The results of our studies and those of other re-
search groups [3, 6] supply evidence that the side-
effects evoked by TNP-470 are fairly limited and re-
versible after treatment, which indicates that this
analogue of fumagilin — TNP-470 is a potentially
valuable antitumour drug.
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